Case Report

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast

Yuki Usui\textsuperscript{a} Ryoichi Matsunuma\textsuperscript{a} Kei Yamaguchi\textsuperscript{a} Ryosuke Hayami\textsuperscript{a} Aya Muramatsu\textsuperscript{b} Makoto Suzuki\textsuperscript{b} Michiko Tsuneizumi\textsuperscript{a}

\textsuperscript{a}Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan; \textsuperscript{b}Department of Pathology, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan

Keywords
Pathological complete response · Breast cancer · Squamous cell carcinoma

Abstract
Squamous cell carcinoma (SCC) of the breast is a rare malignancy that usually has a triple-negative phenotype and poor clinical outcomes. Because HER2-positive SCC of the breast is extremely rare, its clinicopathologic features are understudied, and the effects of neoadjuvant chemotherapy including anti-HER2-targeted therapy on the tumor are unclear, although treatment resistance was described in some reports. In this study, we reported a case of HER2-positive SCC of the breast in which a pathological complete response to neoadjuvant chemotherapy was observed.

Introduction
Squamous cell carcinoma (SCC) of the breast is a rare malignancy that accounts for $<0.2\%$ of all breast cancers [1]. SCC can be diagnosed when $>90\%$ of the malignant cells are of the squamous type [2]. The origin of the SCC component remains unclear. Some authors hypothesized that SCC of the breast arises as an extensive and prominent squamous metaplasia in invasive duct carcinoma [3, 4], whereas others suspected that SCC initially presents as benign
breast conditions such as abscesses or develops in association with implants [5–7]. Recently, some reports stated that SCC and its adjacent invasive ductal carcinoma component shared the same origin, but their transcription landscape and driven pathways differed [8–10].

Fig. 1. a Mammography revealed a mass with branching-type calcifications and enlarged nodes. b Ultrasonography disclosed a hypoechoic and heterogeneous solid mass in the right breast. c MRI revealed a rim-enhancing mass, localized skin thickening, and enhancement overlying the tumor consistent with skin invasion. d Computed tomography identified axillary lymph node metastasis (upper) and subclavicular lymph node metastasis (lower).
The immunohistochemistry profile of SCC often indicates a triple-negative subtype, suggesting aggressive histological features and poor outcomes [11]. HER2-positive breast cancer is rather unusual in SCC, and all available data regarding HER2-positive SCC of the breast were generated by case reports and small retrospective studies [1, 12–16], and the clinicopathologic features of this rare subtype of SCC have not been described in detail. In this study, we reported a case of HER2-positive SCC of the breast, an extremely rare breast cancer, which exhibited a pathological complete response to neoadjuvant chemotherapy.

**Case Report**

A 48-year-old woman presented with a right breast lump in May 2019. Physical examination revealed a 5-cm lump with redness on her right lower breast and the absence of axillary lymphadenopathy. Diagnostic mammography detected a mass with branching-type calcifications. Breast ultrasonography revealed a 42-mm hypoechoic and heterogeneous solid mass, and contrast-enhanced MRI disclosed a 47-mm round, centrally necrotic mass with rim enhancement and invasion-suggesting enhancement into the overlying skin in the right breast. Additionally, thoracic and abdominal CT revealed the absence of distant organ metastases and axillary and subclavicular lymph node metastases (i.e., stage IIIC T4bN3aM0; Fig. 1). Biopsy of the breast mass revealed SCC. Immunohistochemistry confirmed that the lesion was positive for HER2, cytokeratin 5/6 (CK5/6), and EGFR and negative for ER and PgR (Fig. 2). The patient completed 4 cycles of dose-dense doxorubicin and cyclophosphamide every 2 weeks, followed by 4 cycles of trastuzumab plus pertuzumab and docetaxel every 3 weeks as neoadjuvant chemotherapy. Contrast-enhanced MRI
after neoadjuvant chemotherapy revealed that the tumor was considerably decreased in size to an 18-mm irregular mass without skin invasion, and CT revealed regression of the axillary and subclavicular lymph nodes, indicating a partial response (Fig. 3a–b). Subsequently, mastectomy and axillary dissection were performed. The histological therapeutic effect was pathological complete response in the both tumor and lymph nodes (Fig. 3c). Postmastectomy radiotherapy and 14 cycles of trastuzumab plus pertuzumab were provided as adjuvant treatment. The patient has not experienced recurrence as of 22 months after the surgery.

Discussion

There are limited data from studies with small sample sizes regarding HER2-positive SCC of the breast. Barnes et al. [17] reported that 1 of 26 patients with adenosquamous carcinoma (4%) displayed HER2/neu overexpression. Shui et al. [15] reported that 3 of 30 cases of SCC
(10%) were HER2 positive. Lei et al. [16] reported that 13 of 58 cases of metaplastic SCC (22%) were HER2 positive. Additionally, because few clinicopathologic and therapeutic studies have examined HER2-positive SCC because of the rarity of the disease, the effect of neoadjuvant chemotherapy is unclear. Because SCC is generally considered an aggressive, treatment-refractory disease with a poor prognosis, some physicians believe that HER2-positive SCC of the breast is likely to display primary resistance to HER2-targeted therapies. Furthermore, 1 report indicated that combined overexpression of EGFR and CK5/6 was the only independent prognostic factor for SCC of the breast [18].

Some reports based on immunohistochemical assessment suggested that a subtype of SCC of the breast coexpresses basal CKs and HER2 protein, which is the so-called basal-HER2 subtype (ER negative and basal CK positive) [19–21]. They considered that the basal-HER2 subtype is linked to resistance to anti-HER2 agents and chemotherapy because this subtype was associated with poorer survival than basal-like and HER2-positive breast cancers [20, 22].

In the present case, the immunohistochemistry profile of SCC of the breast disclosed HER2-positive breast cancer that was ER negative, CK5/6 positive, and EGFR positive on immunohistochemistry, suggestive of the basal-HER2 subtype. Although this breast cancer might be a treatment-refractory disease according to some previous reports, a pathological complete response was obtained via neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide, followed by pertuzumab and trastuzumab plus docetaxel, with both therapies contributing to substantial tumor regression, and the patient has not experienced recurrence within 2 years after surgery.

**Acknowledgments**

We would like to thank the staff and nurses for their kind cooperation. We would also like to thank the patient and her family.

**Statement of Ethics**

The patient provided written informed consent for publication of this case, including images. The study was exempt from ethics committee approval since maximum measures were taken to eliminate any patient identifiers.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

The authors have no funding source to report.

**Author Contributions**

R. Matsunuma and Y. Usui wrote the main manuscript. All authors critically reviewed the manuscript for content.
Data Availability Statement

All data generated during this study are included in this article. Further enquiries can be directed to the corresponding author.

References

1. Nayak A, Wu Y, Gilcrease MZ. Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival. Am J Surg Pathol. 2013 Jun;37(6):867–73.
2. Rosen PP. Rosen’s breast pathology. Lippincott Williams & Wilkins; 2001.
3. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer. 1990 Jan 15;65(2):272–6.
4. Stevenson JT, Graham DJ, Khiyami A, Mansour EG. Squamous cell carcinoma of the breast: a clinical approach. Ann Surg Oncol. 1996 Jul;3(4):367–74.
5. Tan YM, Yeo A, Chia KH, Wong CY. Breast abscess as the initial presentation of squamous cell carcinoma of the breast. Eur J Surg Oncol. 2002 Feb;28(1):91–3.
6. Salemis NS. Breast abscess as the initial manifestation of primary pure squamous cell carcinoma: a rare presentation and literature review. Breast Dis. 2011;33(3):125–31.
7. Zomerlei TA, Samarghandi A, Terando AM. Primary squamous cell carcinoma arising from a breast implant capsule. Plast Reconstr Surg Glob Open. 2015 Dec;3(12):e506.
8. Avigdor BE, Beierl K, Gocke CD, Zabransky DJ, Cravero K, Kyker-Snowman K, et al. Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component. Clin Cancer Res. 2017 Aug 15;23(16):4875–84.
9. Ng CKY, Piscuoglio S, Geyer FC, Burke KA, Pareja F, Eberle CA, et al. The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin Cancer Res. 2017 Jul 15;23(14):3859–70.
10. Piscuoglio S, Ng CKY, Geyer FC, Burke KA, Cowell CF, Martelotto LG, et al. Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. NPJ breast cancer. 2017;3:48.
11. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011 Feb;24(2):157–67.
12. Hennessy BT, Krishnamurthi S, Giordano S, Buchholz TA, Kau SW, Duan Z, et al. Squamous cell carcinoma of the breast. J Clin Oncol. 2005 Nov 1;23(31):7827–35.
13. Karamouzis MV, Fida A, Apostolidis N, Rigatos G. A case of HER-2(+) squamous cell breast carcinoma: an unusual presentation of an unusual clinical entity. Eur J Surg Oncol. 2006 Dec;32(10):1250–1.
14. Grenier J, Soria JC, Mathieu MC, Andre F, Abdelloua S, Velasco V, et al. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res. 2007 Jan-Feb;27(1b):547–55.
15. Shui R, Li A, Yang F, Zhou X, Yu B, Xu X, et al. Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. Int J Clin Exp Pathol. 2014;7(8):5203–9.
16. Lei T, Pu T, Wei B, Fan Y, Yang L, Shen M, et al. Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast. J Clin Pathol. 2020 Nov 19;jclinpath-2020-206468.
17. Barnes PJ, Boutilier R, Chisson D, Rayson D. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat. 2005 May;91(2):173–8.
18. Wang J, Zhang X, He J, Yang M, Tang J, Li X, et al. Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 2014 Sep;31(9):172.
19. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185–91.
20. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008 Feb;39(2):167–74.
21. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010 May 25;7(5):e1000279.
22. Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol. 2012 Mar;19(3):935–40.